glp-1 drugs and crohn's disease Role of glucagon-like peptides in inflammatory bowel diseases—current knowledge future perspectives | Naunyn-Schmiedeberg's Archives of Pharmacology Glucagon-like peptide-1 (GLP-1) receptor agonists

A board-certified clinician who reviews your intake and approves your plan

Key Findings: - Increased risk of going over recommended weight gain limits - Higher chances of preterm birth (from 13% to 17%) - Rising cases of gestational diabetes (15% to 20%) - Nearly half faced high blood pressure issues While baby sizes and C-section rates remained similar, the impact on maternal health is significant

Ozempic and metformin are both popular weight loss drugs, but they work very differently, and only one is FDA approved to treat obesity.

In this review, we aimed to summarize the changes in endogenous GLP-1 levels and their association with weight loss after MBS, describe the effects of GLP-1-RA use on weight loss after MBS, and emphasize metabolic adaptations in light of the recent literature

These milestones will redefine how obesity care is delivered, marking a turning point that will shape the markets trajectory for 2026 and the years to come

Post-Feb 2026 FDA crackdown, we ranked 8 top GLP-1 programs for women over 40